Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Phase 2

Conditions: Toxicity
Non-small Cell Lung Cancer

First Posted Date: 2010-09-01

Last Posted Date: 2010-09-03

Lead Sponsor: Fudan University

Target Recruit Count: 68

Registration Number: NCT01192243

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Icotinib
Drug: Gefitinib

First Posted Date: 2009-12-30

Last Posted Date: 2014-02-14

Lead Sponsor: Betta Pharmaceuticals Co., Ltd.

Target Recruit Count: 399

Registration Number: NCT01040780

Locations: 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
the Second Xiangya Hospital，Central South University, Changsha, Hunan, China

and more 24 locations

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer
Carcinoma, Non-Small Cell-Lung
Respiratory Tract Neoplasms
Lung Neoplasms

Interventions: Biological: AV-299 + gefitinib
Drug: Gefitinib

First Posted Date: 2009-12-25

Last Posted Date: 2015-04-08

Lead Sponsor: AVEO Pharmaceuticals, Inc.

Target Recruit Count: 203

Registration Number: NCT01039948

Locations: 🇹🇭
Investigational Site 24, Chiang Mai, Thailand
🇵🇭
Investigational Site 14, Quezon City, Philippines
🇹🇭
Investigational Site 23, Bangkok, Thailand

and more 23 locations

Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2009-12-03

Last Posted Date: 2013-08-12

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 26

Registration Number: NCT01024712

Locations: 🇨🇳
Cancer Institute Hospital, Chinese Academy of Medical Sciences, Beijing, China

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Phase 3

Completed

Conditions: Thoracic Neoplasms

Interventions: Drug: erlotinib
Drug: gefitinib

First Posted Date: 2009-12-02

Last Posted Date: 2017-03-01

Lead Sponsor: Chinese Society of Lung Cancer

Target Recruit Count: 256

Registration Number: NCT01024413

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2009-11-23

Last Posted Date: 2015-07-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 236

Registration Number: NCT01017874

Locations: 🇹🇭
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hat Yai, Thailand

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Phase 2

Suspended

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: gefitinib

First Posted Date: 2009-09-29

Last Posted Date: 2015-12-22

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 102

Registration Number: NCT00986284

Locations: 🇨🇳
Tianjin Cancer Institute & Hospital, Tianjin, Tianjin, China

Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2009-08-10

Last Posted Date: 2013-08-02

Lead Sponsor: National Cancer Center, Korea

Target Recruit Count: 242

Registration Number: NCT00955695

Randomized Gefitinib Trial

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gefitinib
Drug: Platinum

First Posted Date: 2008-12-11

Last Posted Date: 2012-04-23

Lead Sponsor: Fondazione Humanitas per la Ricerca

Target Recruit Count: 1

Registration Number: NCT00807066

Locations: 🇮🇹
Fondazione Humanitas per la Ricerca, Rozzano, Milan, Italy

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

Phase 4

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Gefitinib
Drug: Placebo

First Posted Date: 2008-10-10

Last Posted Date: 2016-02-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 296

Registration Number: NCT00770588

Locations: 🇨🇳
Research Site, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy